Victory Capital Management
ESPR

Victory Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Victory Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.3K Buy
28,268
+61
+0.2% +$171 ﹤0.01% 2339
2026
Q1 		$77.3K Sell
28,207
-567,775
-95% -$1.8M ﹤0.01% 2287
2025
Q4 		$2.21M Buy
595,982
+169,116
+40% +$546K ﹤0.01% 1563
2025
Q3 		$1.13M Buy
426,866
+403,664
+1,740% +$781K ﹤0.01% 1781
2025
Q2 		$22.8K Sell
23,202
-420
-2% -$421 ﹤0.01% 2436
2025
Q1 		$34K Sell
23,622
-149,461
-86% -$275K ﹤0.01% 2393
2024
Q4 		$381K Buy
173,083
+148,456
+603% +$346K ﹤0.01% 2097
2024
Q3 		$40.6K Buy
24,627
+2,417
+11% +$4.88K ﹤0.01% 2403
2024
Q2 		$49.3K Sell
22,210
-1,969
-8% -$4.63K ﹤0.01% 2370
2024
Q1 		$64.8K Buy
24,179
+8,981
+59% +$21.8K ﹤0.01% 2354
2023
Q4 		$45.4K Buy
15,198
+3,558
+31% +$4.62K ﹤0.01% 2448
2023
Q3 		$11.4K Buy
11,640
+1,372
+13% +$1.99K ﹤0.01% 2478
2023
Q2 		$14.3K Buy
+10,268
New +$14.3K ﹤0.01% 2470
2021
Q3 		– Sell
-17,390
Closed -$368K – 2794
2021
Q2 		$368K Sell
17,390
-689
-4% -$16.6K ﹤0.01% 2346
2021
Q1 		$507K Sell
18,079
-816
-4% -$24.1K ﹤0.01% 2199
2020
Q4 		$491K Sell
18,895
-929
-5% -$27.8K ﹤0.01% 2088
2020
Q3 		$737K Sell
19,824
-7,290
-27% -$289K ﹤0.01% 1831
2020
Q2 		$1.39M Buy
27,114
+13,626
+101% +$570K ﹤0.01% 1570
2020
Q1 		$425K Sell
13,488
-1,421
-10% -$75K ﹤0.01% 1898
2019
Q4 		$889K Buy
14,909
+707
+5% +$31.8K ﹤0.01% 1786
2019
Q3 		$521K Buy
14,202
+13,929
+5,102% +$552K ﹤0.01% 1868
2019
Q2 		$13K Hold
273
– – ﹤0.01% 1802
2019
Q1 		$11K Hold
273
– – ﹤0.01% 1762
2018
Q4 		$13K Sell
273
-52
-16% -$2.5K ﹤0.01% 1754
2018
Q3 		$14K Buy
325
+43
+15% +$1.97K ﹤0.01% 1777
2018
Q2 		$11K Hold
282
– – ﹤0.01% 1809
2018
Q1 		$20K Hold
282
– – ﹤0.01% 1790
2017
Q4 		$19K Hold
282
– – ﹤0.01% 1789
2017
Q3 		$14K Hold
282
– – ﹤0.01% 1794
2017
Q2 		$13K Buy
282
+5
+2% +$184 ﹤0.01% 1790
2017
Q1 		$10K Hold
277
– – ﹤0.01% 1789
2016
Q4 		$3K Buy
277
+17
+7% +$202 ﹤0.01% 1787
2016
Q3 		$4K Buy
260
+18
+7% +$204 ﹤0.01% 1772
2016
Q2 		$2K Buy
242
+5
+2% +$83 ﹤0.01% 1630
2016
Q1 		$4K Buy
237
+18
+8% +$290 ﹤0.01% 1656
2015
Q4 		$5K Buy
219
+12
+6% +$303 ﹤0.01% 1672
2015
Q3 		$5K Buy
207
+20
+11% +$1.25K ﹤0.01% 1613
2015
Q2 		$15K Buy
+187
New +$18.3K ﹤0.01% 1608

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Victory Capital Management's ESPR Position: Q2 2026 in Review

Victory Capital Management increased its Esperion Therapeutics (ESPR) stake by 0.22% in Q2 2026, buying an estimated $171 and bringing the position to 28,268 shares worth $89.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

Victory Capital Management first reported a position in ESPR in Q2 2015 and has held it in 38 quarters since. The position peaked at $2.21M in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Victory Capital Management held 28,268 shares of Esperion Therapeutics worth $89.3K as of Q2 2026.
  • Victory Capital Management bought 61 Esperion Therapeutics shares in Q2 2026, an estimated $171.
  • Esperion Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2339 holding.
  • Victory Capital Management first reported a position in Esperion Therapeutics in Q2 2015 and has held it in 38 quarters since.
  • Victory Capital Management's Esperion Therapeutics position peaked at $2.21M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.